Charles River Labs Stock - Analyst sentiment and technical picture on a quiet news day

Edited by ad hoc news Chart & Technicals Desk. Verified prior to publication on 06/18/2026, 19:03 UTC. Details in the imprint.

Charles River Laboratories (US14149Y1082) stock draws attention today without any new market-moving company announcement. Instead, the focus is on how analysts are positioned and where the shares sit technically on the chart.

Analyst consensus snapshot

On the analyst side, sentiment on Charles River Laboratories remains broadly constructive but not euphoric. According to recent consensus data compiled by MarketScreener, the stock carries a mixed spread of Buy, Hold and Sell ratings, with an average analyst rating in the Hold-to-Buy range.

The same overview points to an average 12-month price target moderately above the current share price, indicating some upside in brokers’ base cases but without an aggressive growth call.

How recent ratings line up

Several large investment banks updated their views on Charles River Laboratories earlier this year around the publication of quarterly results, and those stances continue to frame expectations today. An analyst summary on Yahoo Finance shows multiple Buy and Hold recommendations outstanding, with only a small number of more cautious calls.

Against this backdrop, investors are working with a fairly balanced sell-side picture. There is support from growth-oriented houses, yet also a recognition of valuation sensitivity and sector competition in contract research and laboratory services.

Technical picture around key levels

From a chart perspective, Charles River Laboratories shares currently trade below their 52-week high and around the middle of their 52-week range, suggesting a neutral technical stance rather than a clear trend. The latest quote data on Nasdaq shows the stock fluctuating within a broad band established over recent months.

Based on public chart services, the shares are trading around their major moving averages, including the 200-day line, without a decisive break in either direction. This keeps the technical setup balanced, with neither clear bullish momentum nor an evident breakdown.

The business behind the ticker

Charles River Laboratories generates revenue as a global contract research organization, providing non-clinical laboratory services and research models for pharmaceutical, biotech and academic clients. The company supports drug discovery and early development, including toxicology studies, safety assessments and biologics testing.

Where the stock trades today

Charles River Laboratories shares (US14149Y1082) trade on the New York Stock Exchange at around $220 per share as of 06/18/2026, 19:00 UTC.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.